United States Anti-Infective Drugs Market expected to grow at a high CAGR during 2024-2031 | Top Companies - Abbott Laboratories Limited, Cipla Ltd., Glenmark Pharmaceuticals Ltd.

"The Global Anti-Infective Drugs Market is estimated to reach at a high CAGR during the forecast period (2024-2031)." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/anti-infective-drugs-market?sp

United States: Recent Industry Developments

✅ In November 2025, Recce Pharmaceuticals announced patent approval for its synthetic anti-infectives (RECCE® 327/R327 and RECCE® 529/R529) covering novel treatment pathways for bacterial, viral, and multi-drug resistant infections. The patents strengthen the company's global intellectual-property position and support future commercialization efforts in the U.S. and beyond. It signals an increased focus on innovative anti-infective solutions.

✅ In October 2025, Iterum Therapeutics launched ORLYNVAHTM (oral sulopenem) in the U.S., marking the first oral penem antibiotic approved for uncomplicated urinary tract infections in adult women. The launch addresses the urgent need for oral therapies amid rising antimicrobial resistance. It highlights the importance of expanding treatment options in the U.S. anti-infective market.

✅ In September 2025, GlaxoSmithKline (GSK) reported FDA approval of Blujepa® (gep-tid-acin) for uncomplicated UTIs in women and adolescent girls aged 12 and older, acting via a novel mechanism with reduced resistance potential. The company positions the drug to compete in an unmet segment and expand its anti-infective pipeline. It reflects how precision-targeted antibiotics are gaining regulatory support.

✅ In August 2025, Merck & Co. initiated a new clinical trial program combining its PD-1 inhibitor Keytruda with existing anti-infective drugs for treatment-resistant bacterial infections. The study explores synergistic mechanisms to enhance efficacy and reduce treatment duration. It underscores Merck's strategy to expand into combination anti-infective therapies.

Japan: Recent Industry Developments

✅ In November 2025, Recce Pharmaceuticals' Japanese patent grant for RECCE® anti-infectives was recognized as a strategic move to secure deeper access to the Japanese market. The patent enables potential licensing or joint-venture collaborations and positions the company to participate in Japan's advanced infectious-disease sector. It reflects the importance of cross-regional intellectual-property strategy.

✅ In October 2025, Shionogi & Co., Ltd. submitted a supplemental NDA for its oral antiviral Ensitrelvir (Xocova®) to expand indication for post-exposure prophylaxis of COVID-19 in patients aged 6 and older. The expansion builds on prior approvals for treatment in older adults and enhances Japan's antiviral toolkit. It demonstrates the growing focus on prophylactic anti-infective therapies.

✅ In September 2025, leading Japanese clinical networks accelerated late-stage development programs for next-generation antibiotics targeting gram-negative superbug pathogens. The initiatives are supported by domestic manufacturers and global partners, reflecting Japan's commitment to combating antimicrobial resistance. It underscores the country's growing role in high-value, specialty anti-infective research.

✅ In August 2025, Astellas Pharma announced clinical trials for its novel antibacterial compounds designed to treat multi-drug resistant infections in hospitals across Japan. The trials focus on safety, efficacy, and rapid pathogen clearance in high-risk populations. It illustrates Japan's proactive approach to addressing emerging infectious threats.

Anti-Infective Drugs Market: Drivers

The anti-infective drugs market is witnessing sustained growth as the global burden of infectious diseases, including bacterial, viral, and fungal infections, continues to rise. These drugs, encompassing antibiotics, antivirals, antifungals, and antiparasitics, play a critical role in preventing and treating infections across healthcare settings. Rising incidences of hospital-acquired infections, respiratory diseases, and emerging viral outbreaks are driving demand. Additionally, increasing awareness of early diagnosis and timely treatment, coupled with expanding access to healthcare in developing regions, is supporting market expansion. The growth of immunocompromised populations, such as elderly patients and those undergoing chemotherapy, further accentuates the need for effective anti-infective therapies.

Advancements in drug development, including next-generation antibiotics, combination therapies, and targeted antivirals, are enhancing treatment efficacy and addressing drug-resistant strains. Regulatory incentives and fast-track approvals for critical anti-infective agents are accelerating the introduction of innovative drugs to the market. The rising focus on hospital stewardship programs and prophylactic treatments in high-risk patient groups is further driving adoption. Additionally, increasing pharmaceutical R&D investments and collaborations are expanding pipelines for novel compounds. With the ongoing threat of antimicrobial resistance and emerging infectious diseases, the anti-infective drugs market is poised for continuous, innovation-driven growth globally.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/anti-infective-drugs-market?sp

Anti-Infective Drugs Market: Major Players

Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Panacea Biotech Ltd., Novartis AG, Pfizer Ltd., Ranbaxy Laboratories Ltd and Sun Pharmaceutical Industries Ltd.

Segment Covered in the Anti-Infective Drugs Market:

By Product Type
The market is segmented into Antibiotics, Antivirals, Antifungals, and Others. Antibiotics account for the largest share due to their widespread use in treating bacterial infections such as pneumonia and sepsis. Antivirals are gaining momentum with the rising prevalence of viral infections, including HIV and respiratory viruses. Antifungals serve a crucial role in managing fungal infections, particularly among immunocompromised patients, while the others segment covers emerging antimicrobial classes and combination therapies.

By Indication
Based on indication, the market is categorized into HIV Infection, Pneumonia, Respiratory Virus Infection, Sepsis, Tuberculosis, and Other Indications. The HIV infection segment remains a key contributor due to ongoing antiretroviral therapy demand. Pneumonia and respiratory virus infections are also significant drivers, supported by increasing cases of hospital-acquired infections. Sepsis and tuberculosis continue to represent major public health concerns, prompting consistent pharmaceutical development efforts.

By Distribution Channel
The market is further segmented into Hospital Pharmacies, Pharmacy Stores, and Others. Hospital pharmacies dominate the market owing to the high volume of inpatient treatments and availability of prescription-based drugs. Pharmacy stores serve as a major distribution point for outpatient therapies, while the others segment includes online and institutional supply channels, reflecting the growing shift toward digital healthcare delivery.

Research Process:

Both primary and secondary data sources have been used in the Anti-Infective Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Anti-Infective Drugs Market Research Industry:

➠ Who leads the Anti-Infective Drugs industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Anti-Infective Drugs market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Anti-Infective Drugs market growth?
➠ What are the dominant sales and distribution strategies in the Anti-Infective Drugs industry?

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=anti-infective-drugs-market
(Purchase 2 or more Repots and get 50% Discount)

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.